Denosumab reduces risk of fractures in post-menopausal women

N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11.

Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates

J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70

FREEDOM RCT follow-up: Denosumab does not delay fracture healing in osteoporosis patients

J Bone Joint Surg Am. 2012 Oct 24. doi: 10.2106/JBJS.K.00774

Denosumab increases bone mineral density in male patients with low BMD

J Clin Endocrinol Metab. 2012 Sep;97(9):3161-9. doi: 10.1210/jc.2012-1569. Epub 2012 Jun 21

Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies

J Clin Densitom. 2016 Jul-Sep;19(3):346-51

Denosumab and teriparatide significantly improves BMD in patients with osteoporosis

J Clin Endocrinol Metab. 2014 May;99(5):1694-700

Denosumab is superior to alendronate for improving cortical bone porosity post-menopause

Bone. 2014 Feb;59:173-9. doi: 10.1016/j.bone.2013.11.016. Epub 2013 Nov 22.

Denosumab increases BMD and reduces bone turnover vs monthly oral bisphosphonate

Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28.

WCO-IOF: Changes with QCT, DXA, and TBS between denosumab, alendronate, & placebo

Larger BMD gains in osteoporosis patients transitioning to denosumab versus other active controls

Expert Opin Drug Saf. 2018 Apr;17(4):413-428

Denosumab reduces secondary fragility fracture risk in osteoporotic women

Climacteric. 2015 Jun 1:1-23

WCO-IOF 2016: Denosumab versus zoledronic acid following oral bisphosphonate therapy

Efficacy of combined teriparatide & denosumab vs. single-drug treatment for osteoporosis

J Clin Endocrinol Metab. 2016 May;101(5):2023-30

Combined teriparatide and denosumab treatment increased BMD in postmenopausal osteoporosis

Lancet. 2013 Jul 6;382(9886):50-6. doi: 10.1016/S0140-6736(13)60856-9. Epub 2013 May 15

Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis

N Engl J Med. 2016 Oct 20;375(16):1532-1543

Denosumab noninferior to zoledronic acid in the treatment of bone metastasis

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22

Denosumab increases bone mass but does not reduce fracture risk compared to alendronate

Int J Clin Pract. 2012 Apr;66(4):399-408. doi: 10.1111/j.1742-1241.2011.02806.x. Epub 2012 Feb 7

Network meta-analysis of anti-osteoporosis therapies for oral glucocorticoid users

Osteoporos Int. 2016 Jun;27(6):1989-98

Better clinicoradiological results at 3 years with SpineJack vertebral augmentation vs BPK for VCFs

Osteoporos Int. 2019 Mar;30(3):637-645. doi: 10.1007/s00198-018-4773-5

Etidronate, alendronate, and reisendronate significantly reduce the risk of hip fracture

Curr Med Res Opin. 2011 Jun;27(6):1141-8. doi: 10.1185/03007995.2011.570747. Epub 2011 Apr 1